EGFR/HER2-IN-8 (compound 34) is an inhibitor of EGFR, HER2, and DHFR with IC50 values of 0.45 μM, 0.244 μM, and 5.669 μM, respectively. It demonstrates anticancer activity against several cancer cell lines, exhibiting a high safety profile and selectivity indices, making it useful for cancer research [1].

EGFR/HER2-IN-8, at concentrations ranging from 0 to 100 μM over 72 hours, demonstrates significant anticancer efficacy against HepG2, MCF 7, HCT-116, PC-3, and Hela cancer cell lines, while showing preferential cytotoxicity towards these cancer cells over normal WI-38 fetal lung fibroblast cells. The compound's cytotoxic effectiveness was quantified by IC50 values of 7.34 μM for HepG2, 5.19 μM for MCF 7, 9.23 μM for HCT-116, 18.5 μM for PC-3, and 13.02 μM for Hela cell lines, indicating robust anti-cancer activity. Conversely, it exhibited minimal cytotoxicity against the WI-38 cell line, with an IC50 value of 67.25 μM,highlighting its selectivity, particularly towards the MCF-7 breast cancer cell line.